在两个结核病高负担国家对微生物学确诊肺结核患者的密切接触者开展社区与全面结核检测:一项实用性整群随机对照试验的研究方案
该方案计划在莱索托和坦桑尼亚开展实用性整群随机对照试验,将药物敏感肺结核指示病例及其家庭和社区接触者随机分为全面结核检测组或标准结核筛查组,评估全面检测对结核检出和结核病预防性治疗(TPT) uptake 的效果,并包含卫生经济学、儿科、微生物学和社会行为学四个子研究。
要点
- 全面结核检测指不论症状对高危人群进行结核检测,可能发现症状筛查漏诊的病例。
- 研究在莱索托和坦桑尼亚招募微生物学确诊的药物敏感肺结核指示病例及其接触者。
- 主要评估全面检测对结核检出和符合条件接触者TPT uptake的效果,并包含成本效果分析。
核心结论
- 该试验旨在为更密集的结核病例发现方法提供证据,假设其可提高结核病例发现的成本效果。
- 研究还将为结核高负担国家提供证据,这些国家的成本结构与既往成本效果分析所在的中低负担环境不同。
研究设计与样本
- 实用性整群随机对照试验,在莱索托和坦桑尼亚开展。
- 招募年龄≥18岁、至少有一名接触者、且在诊断后≤6周内微生物学确诊的药物敏感肺结核指示病例。
- 每个指示病例及其接触者随机分为全面结核检测组或标准结核筛查组。
- 研究包含卫生经济学与建模、儿科、微生物学和社会行为学四个子研究。
- 正式试验前开展准备性横断面研究,确定家庭接触者(HHCs)的结核感染(TBI)患病率、TPT资格,并比较QuantiFERON-TB-Gold-Plus(QFT-Plus)与QIAreach诊断TBI的性能;整群随机试验和社区接触者追踪在II期进行。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tuberculosis (TB) symptom screening and testing using either smear microscopy or GeneXpert MTB/RIF Ultra (Xpert Ultra) have been the mainstay for diagnosing TB disease in case finding. Reliance on symptom-based TB screening results in missed TB cases, and universal TB testing approach might be more suitable to find missing TB cases in high-risk populations. Universal TB testing involves testing for TB disease regardless of TB symptoms in those at risk of TB. However, limited evidence exists to support its adoption including cost-effectiveness. In this study, we will evaluate the effectiveness of universal TB testing for detection of TB and uptake of TB preventive therapy (TPT) among eligible household and community contacts in high TB settings as per country guidelines. METHODS: This is a pragmatic cluster-randomised trial conducted in Lesotho and Tanzania. Drug-sensitive TB (DS-TB) index patients aged ≥ 18 years, who have at least one contact, will be enrolled if they are microbiologically confirmed with TB within ≤ 6 weeks of diagnosis at the time of recruitment by study team at health facilities in selected districts or regions. Each TB index patient and their contact(s) will be randomised into either universal TB testing or standard TB screening arms. Household and community contacts listed by each TB index case will be enumerated and invited to participate in the study after providing informed consent or assent during household visits. The study has four sub-studies including health economics and modelling, paediatrics, microbiology, and socio-behavioural. A preparatory cross-sectional study will be conducted before delivery of the pragmatic cluster-randomised trial. It will determine the prevalence of TB infection (TBI), TPT eligibility in household contacts (HHCs), and compare the performance of QuantiFERON-TB-Gold-Plus (QFT-Plus) and QIAreach for diagnosing TBI among HHCs of TB index patients. Cluster-randomised trial and community contact tracing will be conducted in phase II. SIGNIFICANCE: This trial will provide evidence for a more intensive approach which is hypothesised to increase cost-effectiveness of TB case finding. In addition, it will provide evidence for high TB burden countries with inherently different cost structures compared to intermediate and low burden settings where previous cost-effectiveness analyses have been undertaken. CLINICAL TRIAL REGISTRATION NUMBER: BMC Trial Registry ISRCTN10003903. Registered on December 22, 2020. Protocol version number and date. Version 1.2, dated 15 January 2023. Date recruitment began. 1 March 2022. Estimated date of recruitment completion. 31 July 2025.
引用
- Moyo M, Ntshiqa T, Hamada Y, et al. Community and Universal Testing for TB among close contacts of microbiologically confirmed pulmonary TB patients in two high TB burden countries: a protocol for a pragmatic cluster-randomised control trial. Trials. 2025. PMID: 40790601. doi:10.1186/s13063-025-08978-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。